Using Inhibitory DREADDs to Silence LC Neurons in Monkeys

Area of Science:

• Neuroscience
• Primate Research
• Molecular Biology

Background:

• The locus coeruleus (LC) plays a vital role in cognition and behavior, including attention, decision-making, and stress responses.
• Viral tools have advanced rodent brain research, but primate-specific tools are essential for translational applications.
• Understanding LC function in primates is critical for exploring clinical strategies for neurological disorders.

Purpose of the Study:

• To develop a selective and reversible method for inactivating locus coeruleus (LC) neurons in monkeys.
• To investigate the dose-dependent effects of LC inactivation on cognitive functions.
• To establish a valuable tool for primate research on LC function.

Main Methods:

• Utilized a pharmacogenetic approach employing Designer Receptors Exclusively Activated by Designer Drugs (DREADD).
• Expressed the hM4Di DREADD specifically in noradrenergic LC neurons.
• Administered varying doses of the DREADD activator, deschloroclozapine (DCZ), to modulate LC neuron activity.

Main Results:

• Successfully restricted hM4Di DREADD expression to noradrenergic LC neurons.
• Demonstrated that DCZ dose correlates with the degree of LC neuron inhibition.
• High DCZ doses (>0.3 mg/kg) caused significant LC inhibition and decreased vigilance.
• Lower DCZ doses (<0.3 mg/kg) moderately reduced LC activity without affecting vigilance, enabling cognitive assessments.

Conclusions:

• The DREADD approach offers selective and reversible control over LC neuron activity in monkeys.
• Dose-dependent modulation of LC activity allows for the study of its role in subtle cognitive processes like attention and decision-making.
• This pharmacogenetic tool is essential for advancing primate research on LC function and its translational implications.